Welcome to our dedicated page for GTSIF news (Ticker: GTSIF), a resource for investors and traders seeking the latest updates and insights on GTSIF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GTSIF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GTSIF's position in the market.
Lobe Sciences Ltd. (OTC Pink: GTSIF) announced interim data from preclinical research on a combination therapy of psilocybin and N-Acetylcysteine (NAC), which showed statistically significant improvement in rodent models of mild traumatic brain injury (mTBI) and PTSD. The study, conducted with the University of Miami, revealed that rodents treated with the combination performed significantly better than those on single therapies or placebo (P < 0.000005). The company aims to advance to human clinical trials, although a shortage of psilocybin has delayed future studies.
